Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -3 of 3
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
6/12/2007
 
First Published:
7/1/2000
1.
Phase III Randomized Study of APC8015 in Patients With Asymptomatic Metastatic Hormone Refractory Adenocarcinoma of the Prostate
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Other
DEN-D9901
NCI-G00-1789, NCT00005947
2.
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
D9902B
NCT00065442
Last Modified:
8/20/2007
 
First Published:
12/1/2001
3.
Phase II Study of APC8015 (Provenge) and Bevacizumab in Patients With Progressive Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
Not specified
NCI
UCSF-0155-01
NCI-2617, UCSF-01554, NCT00027599, 2617
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute